Autopsy report · NCT00553813

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

“Insufficient funding”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 6 months before it stopped.
• 23 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Cortice Biosciences, Inc.

Sponsor type

Industry

Conditions

Pancreatic Cancer

Interventions

TPI 287

Participants

23

Sites

4

Countries

Spain, United States

Trials that died the same way

• PROactive Evaluation of Function to Avoid CardioToxicity
  “Insufficient funding/staff” (90% match in meaning)
• A Cardiac Registry to Evaluate and Manage the hsTnI Categorical CVD Risk in Subjects Undergoing Preventive Health Checks (PHC).
  “Unavailable funding” (87% match in meaning)
• PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
  “Funding unavailable” (87% match in meaning)
• Hatha Yoga in Breast Cancer Survivors
  “Insufficient staff and funding” (87% match in meaning)
• EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma.
  “Inadequate funding” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.